Previous 10 |
Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up...
MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD137 UTRECHT, The Netherlands, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody t...
Merus N.V. (NASDAQ: MRUS ) has granted Betta Pharmaceuticals an exclusive license to develop and commercialize Merus Biclonics MCLA-129 in China. Merus will retain all rights outside of China. More news on: Merus, Healthcare stocks news, Read more ...
Merus to retain all global rights outside of China Betta Pharmaceuticals to fund global IND-enabling activities UTRECHT, the Netherlands, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company...
Merus (NASDAQ: MRUS ): Q3 EPS of -€0.47 Revenue of €6.51M (+13.8% Y/Y) Press Release More news on: Merus, Earnings news and commentary, Healthcare stocks news,
Clinical milestones for four lead Biclonics ® programs expected in 2019 Cash expected to be sufficient to fund operations into the second quarter of 2021 UTRECHT, The Netherlands, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we ...
NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Spotify Technology SA (NYSE:SPOT), Vornado Realty Trust (NYSE:VNO), Me...
UTRECHT, The Netherlands, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu, Ph.D., Executive Vice President, Chief Business Officer and...
Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S. Peter B. Silverman, J.D., appointed EVP, General Counsel Jillian Connell joins as VP, Investor Relations and Corporate Communications UTRECHT, The Netherlands, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...